TriGenex

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

Bifidobacterium infantis, Quantity: 3.2 billion CFU; Bifidobacterium longum, Quantity: 4.1 billion CFU; Bifidobacterium breve, Quantity: 4 billion CFU

Verfügbar ab:

Biomedica Nutraceuticals Pty Ltd

INN (Internationale Bezeichnung):

Bifidobacterium breve,Bifidobacterium infantis,Bifidobacterium longum

Darreichungsform:

Capsule, hard

Zusammensetzung:

Excipient Ingredients: microcrystalline cellulose; colloidal anhydrous silica; tricalcium phosphate; tapioca starch; hypromellose; disodium edetate; potable water; potassium acetate; gellan gum

Verabreichungsweg:

Oral

Anwendungsgebiete:

Maintain/support general health and wellbeing ; Maintain/support healthy digestive system function ; Maintain/support healthy digestion ; Maintain/support digestive system health ; Maintain/support intestinal good/beneficial/friendly flora ; Helps restore good/beneficial/friendly intestinal/gut/bowel flora ; Maintain/support immune system health ; Maintain/support healthy immune system function

Produktbesonderheiten:

Visual Identification: ;

Berechtigungsstatus:

Licence status A

Berechtigungsdatum:

2017-06-30